CYTH Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -3778.44% compared to Cyclo Therapeutics's net margin of -49.65%. Cyclo Therapeutics's return on equity of -4056.09% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cyclo Therapeutics has a consensus price target of $3.20, signalling upside risk potential of 52.49%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that NovaBay Pharmaceuticals has higher upside potential than Cyclo Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Cyclo Therapeutics.

Cyclo Therapeutics has a beta of -0.485, which suggesting that the stock is 148.517% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Cyclo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclo Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cyclo Therapeutics quarterly revenues are $233.8K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cyclo Therapeutics's net income of -$8.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Cyclo Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclo Therapeutics is 19.33x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pacira BioSciences has a net margin of -3778.44% compared to Cyclo Therapeutics's net margin of -85.11%. Cyclo Therapeutics's return on equity of -4056.09% beat Pacira BioSciences's return on equity of -10.74%.

Cyclo Therapeutics has a consensus price target of $3.20, signalling upside risk potential of 52.49%. On the other hand Pacira BioSciences has an analysts' consensus of $19.29 which suggests that it could fall by -6.56%. Given that Cyclo Therapeutics has higher upside potential than Pacira BioSciences, analysts believe Cyclo Therapeutics is more attractive than Pacira BioSciences.

Cyclo Therapeutics has a beta of -0.485, which suggesting that the stock is 148.517% less volatile than S&P 500. In comparison Pacira BioSciences has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.508%.

Cyclo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacira BioSciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclo Therapeutics pays -- of its earnings as a dividend. Pacira BioSciences pays out -- of its earnings as a dividend.

Cyclo Therapeutics quarterly revenues are $233.8K, which are smaller than Pacira BioSciences quarterly revenues of $168.6M. Cyclo Therapeutics's net income of -$8.8M is higher than Pacira BioSciences's net income of -$143.5M. Notably, Cyclo Therapeutics's price-to-earnings ratio is -- while Pacira BioSciences's PE ratio is 11.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclo Therapeutics is 19.33x versus 1.62x for Pacira BioSciences. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -3778.44% compared to Cyclo Therapeutics's net margin of -2357.27%. Cyclo Therapeutics's return on equity of -4056.09% beat Palatin Technologies's return on equity of --.

Cyclo Therapeutics has a consensus price target of $3.20, signalling upside risk potential of 52.49%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1404.43%. Given that Palatin Technologies has higher upside potential than Cyclo Therapeutics, analysts believe Palatin Technologies is more attractive than Cyclo Therapeutics.

Cyclo Therapeutics has a beta of -0.485, which suggesting that the stock is 148.517% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Cyclo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclo Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Cyclo Therapeutics quarterly revenues are $233.8K, which are smaller than Palatin Technologies quarterly revenues of $350K. Cyclo Therapeutics's net income of -$8.8M is lower than Palatin Technologies's net income of -$7.8M. Notably, Cyclo Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclo Therapeutics is 19.33x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -3778.44% compared to Cyclo Therapeutics's net margin of --. Cyclo Therapeutics's return on equity of -4056.09% beat Theriva Biologics's return on equity of --.

Cyclo Therapeutics has a consensus price target of $3.20, signalling upside risk potential of 52.49%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 6141.38%. Given that Theriva Biologics has higher upside potential than Cyclo Therapeutics, analysts believe Theriva Biologics is more attractive than Cyclo Therapeutics.

Cyclo Therapeutics has a beta of -0.485, which suggesting that the stock is 148.517% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

Cyclo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclo Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Cyclo Therapeutics quarterly revenues are $233.8K, which are larger than Theriva Biologics quarterly revenues of --. Cyclo Therapeutics's net income of -$8.8M is lower than Theriva Biologics's net income of -$7.7M. Notably, Cyclo Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclo Therapeutics is 19.33x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.